DK2424557T3 - Modificeret compstatin med peptid-backbone og c-terminal modifikationer - Google Patents

Modificeret compstatin med peptid-backbone og c-terminal modifikationer Download PDF

Info

Publication number
DK2424557T3
DK2424557T3 DK10718379.0T DK10718379T DK2424557T3 DK 2424557 T3 DK2424557 T3 DK 2424557T3 DK 10718379 T DK10718379 T DK 10718379T DK 2424557 T3 DK2424557 T3 DK 2424557T3
Authority
DK
Denmark
Prior art keywords
trp
peptide
compound
methyl
compstatin
Prior art date
Application number
DK10718379.0T
Other languages
English (en)
Inventor
John D Lambris
Hongchang Qu
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of DK2424557T3 publication Critical patent/DK2424557T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Claims (16)

1. Forbindelse omfattende et modificeret compstatin-peptid med SEQ ID NO: 1, hvilken er: ICWQDWGHHRCT (cyklisk C2-C12), i hvilken Gly ved position 8 er modificeret til at begrænse backbone-konformationen af peptidet ved den position; hvor backbone begrænses ved at erstatte Gly med N-methyl Gly.
2. Forbindelsen ifølge krav 1, yderligere omfattende erstatning af His ved position 9 med Ala.
3. Forbindelsen ifølge krav 1 eller krav 2, yderligere omfattende erstatning af Val ved position 4 med Trp, 1-methyl Trp eller 1-formyl Trp.
4. Forbindelsen ifølge et hvilket som helst af kravene 1-3, yderligere omfattende erstatning af Trp ved position 7 med halogeneret Trp.
5. Forbindelsen ifølge et hvilket som helst af kravene 1-4, yderligere omfattende acetylering af N-terminal-resten.
6. Forbindelsen ifølge et hvilket som helst af kravene 1-5, yderligere omfattende at erstatte Thr ved position 13 med Ile, Leu, Nle, N-methyl Thr eller N-methyl Ile.
7. Compstatin-analog omfattende et peptid med SEQ ID NO:2, hvilket er: Xaal - Cys - Val - Xaa2 - Gin - Asp - Xaa3 - Gly - Xaa4 - His - Arg - Cys -Xaa5 (cyklisk C2-C12), i hvilket Gly ved position 8 er modificeret til at begrænse backbone-konformationen af peptidet ved den position ved at erstatte Gly med N-methyl Gly, hvor: Xaal er Ile, Val, Leu, Ac-Ile, Ac-Val, Ac-Leu eller et dipeptid omfattende Gly-Ile; Xaa2 erTrp, halogeneret Trp, Trp omfattende en lavere alkoxy- eller lavere alkylsubstituent ved 5 positionen, eller Trp omfattende en lavere alkyl- eller lavere alkanoylsubstituent ved 1 positionen; Xaa3 er Trp eller halogeneret Trp; Xaa4 er His, Ala, Phe eller Trp; og Xaa5 er Thr, Ile, Leu, Nle, N-methyl Thr eller N-methyl Ile, hvor en carboxyterminal -OH afen hvilken som helst af Thr, Ile, Leu, Nle, N-methyl Thr eller N-methyl Ile eventuelt er erstattet af -NH2.
8. Forbindelsen ifølge krav 7, hvor Xaal er Ac-Ile, Xaa2 er 1-methyl-Trp eller 1-formyl-Trp, Xaa3 erTrp, Xaa4 er Ala, og Xaa5 er Thr, Ile, Leu, Nle, N-methyl Thr eller N-methyl Ile.
9. Forbindelsen ifølge krav 7 eller krav 8, hvilken omfatter en hvilken som helst af SEQ ID NOS: 5, 7, 8, 9, 10 eller 11.
10. Forbindelsen ifølge et hvilket som helst af de foregående krav, forbundet til en yderligere komponent, der forlænger in v/Vo-retentionen af forbindelsen.
11. Forbindelsen ifølge krav 10, hvor den yderligere komponent er polyethylenglycol (PEG) eller et albumin-bindende lille molekyle.
12. Forbindelsen ifølge krav 10, hvor den yderligere komponent er et albuminbindende peptid; eventuelt med SEQ ID NO: 14, hvilken er: RLIEDICLPRWGCLWEDD.
13. Forbindelsen ifølge krav 12, hvor forbindelsen og det albumin-bindende peptid er adskilt af en spacer; eventuelt hvor spaceren er et polyethylenglycol-molekyle.
14. Farmaceutisk sammensætning omfattende forbindelsen ifølge et hvilket som helst af de foregående krav og en farmaceutisk acceptabel bærer.
15. Forbindelse ifølge et hvilket som helst af de foregående krav til anvendelse i inhiberingen af komplement-aktivering.
16. In vitro-anvendelse afen forbindelse ifølge et hvilket som helst af kravene 1 til 14 til inhiberingen af komplement-aktivering.
DK10718379.0T 2009-05-01 2010-05-03 Modificeret compstatin med peptid-backbone og c-terminal modifikationer DK2424557T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17457509P 2009-05-01 2009-05-01
US33945810P 2010-03-04 2010-03-04
PCT/US2010/033345 WO2010127336A1 (en) 2009-05-01 2010-05-03 Modified compstatin with peptide backbone and c-terminal modifications

Publications (1)

Publication Number Publication Date
DK2424557T3 true DK2424557T3 (da) 2018-01-22

Family

ID=42245589

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10718379.0T DK2424557T3 (da) 2009-05-01 2010-05-03 Modificeret compstatin med peptid-backbone og c-terminal modifikationer

Country Status (13)

Country Link
US (2) US8946145B2 (da)
EP (1) EP2424557B1 (da)
JP (2) JP5882890B2 (da)
CN (1) CN102458438A (da)
AU (1) AU2010242739B2 (da)
CA (1) CA2760839C (da)
DK (1) DK2424557T3 (da)
ES (1) ES2655389T3 (da)
HU (1) HUE035378T2 (da)
NO (1) NO2424557T3 (da)
PL (1) PL2424557T3 (da)
PT (1) PT2424557T (da)
WO (1) WO2010127336A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US20130324482A1 (en) * 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
WO2012135624A1 (en) 2011-04-01 2012-10-04 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
MX356528B (es) 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
HUE047375T2 (hu) * 2011-09-07 2020-04-28 Univ Pennsylvania Javított farmakokinetikai tulajdonságokkal rendelkezõ compstatin analógok
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
ES2879430T3 (es) * 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2015089368A2 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
WO2015142701A1 (en) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
ES2974107T3 (es) 2015-10-07 2024-06-25 Apellis Pharmaceuticals Inc Regímenes de dosificación
WO2018160889A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
US11965039B2 (en) * 2018-02-27 2024-04-23 Zp Spv 3 K/S Compstatin analogues and their medical uses
AU2019247467B2 (en) 2018-04-06 2023-01-19 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
JP2022553348A (ja) 2019-10-22 2022-12-22 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分Ｃ３ ｉＲＮＡ組成物およびその使用方法
KR20220148811A (ko) 2020-03-04 2022-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
IL297680A (en) 2020-04-30 2022-12-01 Alnylam Pharmaceuticals Inc IRNA compounds complement factor b (cfb) and methods of using them
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AU2022228911A1 (en) 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
EP4401742A2 (en) 2021-09-17 2024-07-24 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023048151A1 (ja) * 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド
EP4423273A1 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
WO2023100852A1 (ja) 2021-11-30 2023-06-08 日本メジフィジックス株式会社 安定化放射性医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU4648197A (en) * 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
AU3485999A (en) 1998-04-10 1999-11-01 Mayo Foundation For Medical Education And Research Neo-tryptophan
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
DK1951279T3 (da) * 2005-10-08 2017-07-31 Apellis Pharmaceuticals Inc Compstatin og analoger deraf til øjensygdomme
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US7888323B2 (en) * 2005-11-28 2011-02-15 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design

Also Published As

Publication number Publication date
ES2655389T3 (es) 2018-02-19
HUE035378T2 (en) 2018-05-02
PT2424557T (pt) 2018-02-05
US20150203539A1 (en) 2015-07-23
CA2760839A1 (en) 2010-11-04
AU2010242739B2 (en) 2016-08-25
JP6106731B2 (ja) 2017-04-05
JP2012525443A (ja) 2012-10-22
CN102458438A (zh) 2012-05-16
US9371365B2 (en) 2016-06-21
EP2424557A1 (en) 2012-03-07
PL2424557T3 (pl) 2018-04-30
AU2010242739A1 (en) 2011-12-08
US8946145B2 (en) 2015-02-03
JP5882890B2 (ja) 2016-03-09
NO2424557T3 (da) 2018-03-24
US20120178694A1 (en) 2012-07-12
WO2010127336A1 (en) 2010-11-04
EP2424557B1 (en) 2017-10-25
JP2016041711A (ja) 2016-03-31
CA2760839C (en) 2019-02-12

Similar Documents

Publication Publication Date Title
DK2424557T3 (da) Modificeret compstatin med peptid-backbone og c-terminal modifikationer
AU2012304442B2 (en) Compstatin analogs with improved pharmacokinetic properties
EP2377877B1 (en) Potent compstatin analogs
US20140113874A1 (en) Modified Compstatin With Improved Stability And Binding Properties
AU2016202286B2 (en) Potent compstatin analogs
AU2006318333B2 (en) Potent compstatin analogs